ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says

Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says